PLOD2 and nonpapillary renal cell carcinoma: Indeed, pharmacological targeting of DCLK1 using the specific inhibitor DCLK1-IN-1 abrogated hypoxia- and PLOD2-induced stemness and EMT activation in ccRCC cell lines in vitro and suppressed growth, EMT, and stemness properties of PLOD2-rich ccRCC xenografts in vivo.